Sandbox:Mitra: Difference between revisions

Jump to navigation Jump to search
Mitra Chitsazan (talk | contribs)
No edit summary
Mitra Chitsazan (talk | contribs)
Undo revision 1647093 by Mitra Chitsazan (talk)
Tag: Undo
Line 7: Line 7:
{{familytree | | | |!| | | | |!| | | | |!| | | |!| | | |!| | | | |!| | | |}}
{{familytree | | | |!| | | | |!| | | | |!| | | |!| | | |!| | | | |!| | | |}}
{{familytree | | | C01 | | | C02 | | | C03 | | C04 | | C05 | | | C06 |C01=<div style="float: Center; text-align: Center; width: 5em; padding:2em;"> •'''Thrmobolytics''' <br> •'''Percutaneous coronary intervention (PCI)''' <br>
{{familytree | | | C01 | | | C02 | | | C03 | | C04 | | C05 | | | C06 |C01=<div style="float: Center; text-align: Center; width: 5em; padding:2em;"> •'''Thrmobolytics''' <br> •'''Percutaneous coronary intervention (PCI)''' <br>
|C02= <div style="float: Center; text-align: Center; width: 5em; padding:2em;"> • '''Avoidance of preload reducing agents''', such as:<br>
|C02= <div style="float: Center; text-align: left;"> • '''Avoidance of preload reducing agents''', such as:<br>
:❑Nitrates  
:❑Nitrates  
:❑Diuretics  
:❑Diuretics  
Line 13: Line 13:
• '''In patients with hypotension (without pulmonary congestion):
• '''In patients with hypotension (without pulmonary congestion):
:❑ Intravenous administration of Fluids (N/S 0.9% at 40mL for 2L, to maintain CVP <15mmHg and PCWP between 18-24 mmHg)
:❑ Intravenous administration of Fluids (N/S 0.9% at 40mL for 2L, to maintain CVP <15mmHg and PCWP between 18-24 mmHg)
|C03=<div style="float: Center; text-align: Center; width: 5em; padding:2em;"> • '''Systemic or pulmonary vasodilators:'''<br>  
|C03=<div style="float: Center; text-align: left;"> • '''Systemic or pulmonary vasodilators:'''<br>  
:❑ Nitroprusside
:❑Nitrosrusside
:❑ Inhaled nitric oxide
:❑Inhaled nitric oxide
|C04=<div style="float: Center; text-align: Center; width: 5em; padding:2em;"> • '''In patients with bradyarrhthmias:'''<br>  
|C04=<div style="float: Center; text-align: left;"> • '''In patients with bradyarrhthmias:'''<br>  
:❑ Atropine
:❑Atropine
:❑ Pacemaker
:❑Pacemaker
• '''In patients with atrioventricular block:'''<br>  
• '''In patients with atrioventricular block:'''<br>  
:❑ Temporary dual-chamber pacemaker
:❑Temporary dual-chamber pacemaker
|C05=<div style="float: Center; text-align: Center; width: 5em; padding:2em;">'''In patients with refractory hypotension:'''<br>   
|C05=<div style="float: Center; text-align: left;"> '''In patients with refractory hypotension:'''<br>   
:❑ Dobutamine (along with fluids)
:❑Dobutamine (along with fluids)
:❑ Other inotropes:
:❑Other inotropes:
*milrinone
*milrinone
*norepinephrine
*norepinephrine
|C06= <div style="float: Center; text-align: Center; width: 5em; padding:2em;"> • '''May be needed in patients with cardiogenic shock secondary to RVMI''':
|C06= <div style="float: Center; text-align: left;"> • '''May be needed in patients with cardiogenic shock secondary to RVMI''':
:❑ Direct RV support
:❑Direct RV support
:❑ Indirect RV support
:❑Indirect RV support
:❑ Biventricular support}}
:❑Biventricular support}}
<br><br>
<br><br>
{{familytree/end}}
{{familytree/end}}

Revision as of 15:40, 4 August 2020



 
 
 
 
 
 
 
 
 
 
 
 
Therapuetic Considerations in RVMI
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reperfusion
 
 
Maintenance of RV preload
 
 
Decrease RV afterload
 
Restoring Rate/Rhythm and AV synchrony
 
Inotropic support
 
 
Mechanical Circulatory Support
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thrmobolytics
Percutaneous coronary intervention (PCI)
 
 
Avoidance of preload reducing agents, such as:
❑Nitrates
❑Diuretics
❑Morphin

In patients with hypotension (without pulmonary congestion):

❑ Intravenous administration of Fluids (N/S 0.9% at 40mL for 2L, to maintain CVP <15mmHg and PCWP between 18-24 mmHg)
 
 
Systemic or pulmonary vasodilators:
❑Nitrosrusside
❑Inhaled nitric oxide
 
In patients with bradyarrhthmias:
❑Atropine
❑Pacemaker

In patients with atrioventricular block:

❑Temporary dual-chamber pacemaker
 
In patients with refractory hypotension:
❑Dobutamine (along with fluids)
❑Other inotropes:
  • milrinone
  • norepinephrine
 
 
May be needed in patients with cardiogenic shock secondary to RVMI:
❑Direct RV support
❑Indirect RV support
❑Biventricular support




Do's

Don'ts